A Post Marketing Safety Study of Lasmiditan (REYVOW®) to describe the use in pregnant women and pregnancy outcomes using the Japan Medical Data Center Database (H8H-MC-B011) First published 20/09/2023 Last updated 23/04/2024 EU PAS number:EUPAS106766 Study Planned